Combination therapy of osimertinib and datopotamab deruxtecan shows promising efficacy in advanced NSCLC, warranting further ...

SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited treatment options. The FDA has granted orphan drug designation (ODD) to ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Sam S. Chang MD, MBA, discusses the findings for mitomycin in for low-grade intermediate-risk nonmuscle-invasive bladder ...

New trial data reveals atebimetinib combined with gemcitabine/nab-paclitaxel significantly improves survival rates in ...

Panelists discuss how to select among the four available JAK inhibitors (Ruxolitinib, Fedratinib, Pacritinib, and Momelotinib) based on patient-specific factors such as anemia, thrombocytopenia, and ...

A panelist discusses how real-world experience with ruxolitinib and belumosidil shows similar response rates to clinical trials (45% and 65% respectively), emphasizes the importance of antimicrobial ...

During a live event, Binod Dhakal, MD, and participants discussed their experience using selinexor in the second line and ...

The survival benefit with cadonilimab in cervical cancer in the overall phase 3 COMPASSION-16 study population was sustained across prespecified subgroups.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

During a live event, Saby George, MD, and participants discussed tolerability concerns in patients with recurrent renal cell ...